HK1247610A1 - 作為nk1拮抗劑的哌啶衍生物 - Google Patents

作為nk1拮抗劑的哌啶衍生物

Info

Publication number: HK1247610A1
Authority: HK; Hong Kong
Prior art keywords: antagonists; piperidine derivatives; piperidine; derivatives
Prior art date: 2004-07-01

Application number

HK18106977.4A

Other languages

English (en)

Inventor

Anandan Palani

Neng-Yang Shih

Xianhai Huang

Dong Xiao

Sunil Paliwal

Hon-Chung Tsui

Michelle Laci Wrobleski

Ashwin U Rao

Cheng Wang

Sapna S Shah

Original Assignee

Opko Health Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-01

Filing date

2018-05-28

Publication date

2018-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35453353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1247610(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-05-28 Application filed by Opko Health Inc filed Critical Opko Health Inc

2018-09-28 Publication of HK1247610A1 publication Critical patent/HK1247610A1/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Obesity (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)
Anesthesiology (AREA)
Reproductive Health (AREA)

HK18106977.4A 2004-07-01 2018-05-28 作為nk1拮抗劑的哌啶衍生物 HK1247610A1 (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US58450204P	2004-07-01	2004-07-01

Publications (1)

Publication Number	Publication Date
HK1247610A1 true HK1247610A1 (zh)	2018-09-28

Family

ID=35453353

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK07107432.4A HK1102962A1 (zh)	2004-07-01	2007-07-11	作為拮抗劑的哌啶衍生物
HK18106977.4A HK1247610A1 (zh)	2004-07-01	2018-05-28	作為nk1拮抗劑的哌啶衍生物

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HK07107432.4A HK1102962A1 (zh)	2004-07-01	2007-07-11	作為拮抗劑的哌啶衍生物

Country Status (26)

Country	Link
US (6)	US7709641B2 (zh)
EP (3)	EP1799666B1 (zh)
JP (1)	JP2008505107A (zh)
KR (1)	KR101228282B1 (zh)
CN (1)	CN101006074B (zh)
AR (2)	AR049655A1 (zh)
AU (1)	AU2005262330B2 (zh)
BR (1)	BRPI0512958A (zh)
CA (1)	CA2570197C (zh)
EC (1)	ECSP067123A (zh)
ES (2)	ES2576555T3 (zh)
HK (2)	HK1102962A1 (zh)
HU (1)	HUE027791T2 (zh)
IL (1)	IL180329A0 (zh)
MX (1)	MX2007000030A (zh)
MY (1)	MY142804A (zh)
NO (1)	NO340368B1 (zh)
NZ (1)	NZ552059A (zh)
PE (1)	PE20060483A1 (zh)
PL (1)	PL1799666T3 (zh)
PT (1)	PT1799666E (zh)
RU (1)	RU2408591C9 (zh)
SG (2)	SG154443A1 (zh)
TW (1)	TWI348467B (zh)
WO (1)	WO2006007540A2 (zh)
ZA (1)	ZA200610666B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20030762A1 (es) *	2001-12-18	2003-09-05	Schering Corp	Compuestos heterociclicos como antagonistas nk1
ES2576555T3 (es)	2004-07-01	2016-07-08	Opko Health, Inc.	Derivados de piperidina como antagonistas de NK1
EP2004148B1 (en)	2006-04-05	2015-07-15	OPKO Health, Inc.	Pharmaceutical formulations comprising salts of (5S,8S)-8-[{(1 R)-1-(3,5-Bis-trifluoromethyl)phenyl]- ethoxy}-methyl]-8-phenyl-1 ,7-diazaspiro[4.5]decan-2-one and their medical use
WO2007117486A2 (en) *	2006-04-05	2007-10-18	Schering Corporation	Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
AR066191A1 (es)	2007-03-22	2009-08-05	Schering Corp	Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
WO2009000038A1 (en) *	2007-06-28	2008-12-31	Cnsbio Pty Ltd	Combination methods and compositions for treatment of neuropathic pain
US8138168B1 (en)	2007-09-26	2012-03-20	Takeda Pharmaceutical Company Limited	Renin inhibitors
PT2346823E (pt)	2008-09-05	2015-11-26	Opko Health Inc	Intermediários para a síntese de compostos 8-[{1-(3,5-bis(trifluorometil)fenil)-etóxi}-metil]-8-fenil-1,7-diazaspiro[ 4.5]decan-2-ona
BR112012003263A2 (pt) *	2009-08-14	2015-09-22	Opko Health Inc	formulações intravenosas de antagonistas de neuroquinina-1
JP2013510145A (ja) *	2009-11-09	2013-03-21	メディヴィル・アクチエボラーグ	１，３−オキサゾリジン化合物およびレニン阻害剤としてのそれらの使用方法
WO2011144656A1 (en)	2010-05-19	2011-11-24	Sandoz Ag	Preparation of posaconazole intermediates
CA2798010C (en)	2010-05-19	2018-09-25	Sandoz Ag	Purification of posaconazole and of posaconazole intermediates
JP5956980B2 (ja)	2010-05-19	2016-07-27	サンド・アクチエンゲゼルシヤフト	キラル化合物の調製の方法
JP6013326B2 (ja) *	2010-05-19	2016-10-25	サンド・アクチエンゲゼルシヤフト	キラルトリアゾロンの調製のための方法
US9493428B2 (en)	2011-06-16	2016-11-15	Sandoz Ag	Process for the preparation of a chiral compound
JP2014530249A (ja)	2011-10-18	2014-11-17	ヘルシンヘルスケアソシエテアノニム	ネツピタントおよびパロノセトロンの治療学的組合せ
CN108025012A (zh) *	2015-07-15	2018-05-11	Opko健康公司	用于治疗疾病的杂芳基甲腈
CN108148060B (zh) *	2016-12-05	2020-06-19	四川科伦博泰生物医药股份有限公司	取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途
WO2020048827A1 (en)	2018-09-03	2020-03-12	Bayer Aktiengesellschaft	1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048828A1 (en)	2018-09-03	2020-03-12	Bayer Pharma Aktiengesellschaft	5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
CN114958325B (zh) *	2021-02-24	2023-06-27	中国石油化工股份有限公司	一种耐高温缓蚀剂、制备方法及其在井筒防腐中的应用
WO2024084360A1 (en)	2022-10-18	2024-04-25	Pfizer Inc.	Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024084363A1 (en)	2022-10-18	2024-04-25	Pfizer Inc.	Use of patatin-like phospholipase domain-containing protein 3 compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2146767A1 (en)	1992-10-28	1994-05-11	Timothy Harrison	4-arylmethyloxymethyl piperidines as tachykinin antagonists
JPH08504435A (ja) *	1992-12-14	1996-05-14	メルクシヤープエンドドームリミテツド	タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
LT3300B (en) *	1992-12-23	1995-06-26	Schering Corp	Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5760018A (en)	1994-01-13	1998-06-02	Merck Sharp & Dohme Ltd.	Gem-disubstituted azacyclic tachykinin antagonists
AU3716997A (en)	1996-07-17	1998-02-09	Merck & Co., Inc.	Alteration of circadian rhythmicity with a tachykinin antagonist
US6117855A (en)	1996-10-07	2000-09-12	Merck Sharp & Dohme Ltd.	Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AU735760B2 (en)	1997-04-24	2001-07-12	Merck Sharp & Dohme Limited	Use of a NK-1 receptor antagonist and an SSRI for treating obesity
US6436928B1 (en)	1999-12-17	2002-08-20	Schering Corporation	Selective neurokinin antagonists
ATE374183T1 (de) *	2001-11-13	2007-10-15	Schering Corp	Nk1-antagonisten
PE20030762A1 (es) *	2001-12-18	2003-09-05	Schering Corp	Compuestos heterociclicos como antagonistas nk1
ES2576555T3 (es)	2004-07-01	2016-07-08	Opko Health, Inc.	Derivados de piperidina como antagonistas de NK1

2005
- 2005-06-29 ES ES05787862.1T patent/ES2576555T3/es active Active
- 2005-06-29 CN CN2005800285965A patent/CN101006074B/zh not_active Expired - Fee Related
- 2005-06-29 MY MYPI20052967A patent/MY142804A/en unknown
- 2005-06-29 ES ES12169655.3T patent/ES2632413T3/es active Active
- 2005-06-29 KR KR1020067027877A patent/KR101228282B1/ko active IP Right Grant
- 2005-06-29 NZ NZ552059A patent/NZ552059A/en not_active IP Right Cessation
- 2005-06-29 AR ARP050102686A patent/AR049655A1/es not_active Application Discontinuation
- 2005-06-29 AU AU2005262330A patent/AU2005262330B2/en not_active Ceased
- 2005-06-29 EP EP05787862.1A patent/EP1799666B1/en active Active
- 2005-06-29 SG SG200904485-0A patent/SG154443A1/en unknown
- 2005-06-29 EP EP12169655.3A patent/EP2522664B1/en active Active
- 2005-06-29 PT PT05787862T patent/PT1799666E/pt unknown
- 2005-06-29 SG SG2012096624A patent/SG187416A1/en unknown
- 2005-06-29 BR BRPI0512958-3A patent/BRPI0512958A/pt not_active Application Discontinuation
- 2005-06-29 CA CA2570197A patent/CA2570197C/en not_active Expired - Fee Related
- 2005-06-29 RU RU2007103611/04A patent/RU2408591C9/ru not_active IP Right Cessation
- 2005-06-29 PL PL05787862.1T patent/PL1799666T3/pl unknown
- 2005-06-29 HU HUE05787862A patent/HUE027791T2/en unknown
- 2005-06-29 JP JP2007519458A patent/JP2008505107A/ja active Pending
- 2005-06-29 EP EP17165369.4A patent/EP3269713A1/en not_active Withdrawn
- 2005-06-29 WO PCT/US2005/023427 patent/WO2006007540A2/en active Application Filing
- 2005-06-29 MX MX2007000030A patent/MX2007000030A/es active IP Right Grant
- 2005-06-30 TW TW094122193A patent/TWI348467B/zh not_active IP Right Cessation
- 2005-06-30 US US11/172,289 patent/US7709641B2/en active Active
- 2005-06-30 PE PE2005000764A patent/PE20060483A1/es active IP Right Grant
2006
- 2006-12-18 ZA ZA200610666A patent/ZA200610666B/xx unknown
- 2006-12-25 IL IL180329A patent/IL180329A0/en not_active IP Right Cessation
- 2006-12-27 EC EC2006007123A patent/ECSP067123A/es unknown
2007
- 2007-01-31 NO NO20070588A patent/NO340368B1/no not_active IP Right Cessation
- 2007-07-11 HK HK07107432.4A patent/HK1102962A1/zh not_active IP Right Cessation
2010
- 2010-03-30 US US12/750,420 patent/US8026364B2/en active Active
2011
- 2011-09-26 US US13/245,403 patent/US8754216B2/en active Active
2014
- 2014-06-13 US US14/304,163 patent/US9469629B2/en not_active Expired - Fee Related
2016
- 2016-02-29 AR ARP160100524A patent/AR103812A2/es unknown
- 2016-10-14 US US15/293,962 patent/US9969711B2/en active Active
2018
- 2018-03-28 US US15/938,409 patent/US20180215729A1/en not_active Abandoned
- 2018-05-28 HK HK18106977.4A patent/HK1247610A1/zh unknown

Also Published As

Publication number	Publication date
HK1102962A1 (zh)	2007-12-07
EP1799666A2 (en)	2007-06-27
HUE027791T2 (en)	2016-11-28
ES2632413T3 (es)	2017-09-13
US20100190759A1 (en)	2010-07-29
ZA200610666B (en)	2008-06-25
US20140296196A1 (en)	2014-10-02
PE20060483A1 (es)	2006-06-23
AR049655A1 (es)	2006-08-23
WO2006007540A2 (en)	2006-01-19
CA2570197A1 (en)	2006-01-19
BRPI0512958A (pt)	2008-04-22
JP2008505107A (ja)	2008-02-21
ES2576555T3 (es)	2016-07-08
US20060223804A1 (en)	2006-10-05
EP3269713A1 (en)	2018-01-17
WO2006007540A3 (en)	2006-04-13
CN101006074B (zh)	2012-02-15
TWI348467B (en)	2011-09-11
AU2005262330A1 (en)	2006-01-19
TW200613302A (en)	2006-05-01
ECSP067123A (es)	2007-01-26
NZ552059A (en)	2010-12-24
NO340368B1 (no)	2017-04-10
RU2408591C2 (ru)	2011-01-10
US8754216B2 (en)	2014-06-17
NO20070588L (no)	2007-03-23
US8026364B2 (en)	2011-09-27
CN101006074A (zh)	2007-07-25
CA2570197C (en)	2013-09-10
US9469629B2 (en)	2016-10-18
US20120295879A1 (en)	2012-11-22
AR103812A2 (es)	2017-06-07
KR101228282B1 (ko)	2013-01-31
US7709641B2 (en)	2010-05-04
PT1799666E (pt)	2016-06-17
RU2007103611A (ru)	2008-08-10
AU2005262330B2 (en)	2012-05-24
EP2522664B1 (en)	2017-04-12
US20170029403A1 (en)	2017-02-02
SG154443A1 (en)	2009-08-28
EP2522664A1 (en)	2012-11-14
US9969711B2 (en)	2018-05-15
MX2007000030A (es)	2007-03-07
SG187416A1 (en)	2013-02-28
KR20070031963A (ko)	2007-03-20
US20180215729A1 (en)	2018-08-02
RU2408591C9 (ru)	2011-04-27
PL1799666T3 (pl)	2016-09-30
MY142804A (en)	2011-01-14
IL180329A0 (en)	2007-07-04
EP1799666B1 (en)	2016-03-16

Publication	Publication Date	Title
HK1247610A1 (zh)	2018-09-28	作為nk1拮抗劑的哌啶衍生物
IL187984A0 (en)	2008-03-20	Piperidine derivatives useful as histamine h3 antagonists
IL180547A0 (en)	2007-06-03	Novel piperidine derivatives as histamine
IL180548A0 (en)	2007-06-03	Piperidine derivatives as histamine h3 receptor ligands
ZA200800320B (en)	2009-02-25	Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
IL185326A0 (en)	2008-02-09	PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS
ZA200709147B (en)	2009-08-26	Pyrimidindione derivatives as prokineticin 2 receptor antagonists
IL178461A0 (en)	2007-02-11	Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
IL183140A0 (en)	2007-09-20	Substituted benzoquinolizine derivatives
IL179888A0 (en)	2007-05-15	Compounds as ccr5 antagonists
IL237513A0 (en)	2015-04-30	Piperazindiones as oxytocin receptor antagonists
IL178622A0 (en)	2007-02-11	Piperazinylpiperidine derivatives as chemokine receptor antagonists
EP1758458A4 (en)	2009-12-09	COMPOSITIONS CONTAINING OPIOIDANT AGONISTS
ZA200806065B (en)	2009-07-29	Oxazoloisoquinoline derivatives as thrombin receptor antagonists
ZA200803454B (en)	2009-04-29	Piperazine derivatives useful as CCR5 antagonists
AP2006003840A0 (en)	2006-12-31	Indole-2-carboxamidine derivatives as NMDA receptor antagonists
ZA200802339B (en)	2009-10-28	Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
IL188371A0 (en)	2008-04-13	Novel piperidine derivatives
HU0501169D0 (en)	2006-02-28	New phenantridine derivatives as selective bradykinin b1 receptor antagonists
EP1736474A4 (en)	2010-04-21	piperidine
ZA200709230B (en)	2008-10-29	Novel piperidine derivatives
IL180702A0 (en)	2007-06-03	Dimeric piperidine derivatives
ZA200800374B (en)	2008-12-31	Novel piperidine derivatives
GB0409607D0 (en)	2004-06-02	Antagonist
GB0304901D0 (en)	2003-04-09	Novel aminopyridine derivatives as mGIuR5 antagonists